Search results
IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High
Investor's Business Daily· 50 minutes agoIn the patients who worsened while taking a prior biologic, 43.4% of mirikizumab patients entered...
J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial
Clinical Trials Arena via Yahoo Finance· 5 hours agoJ&J’s Tremfya is expected to be the successor to the company’s IL-12/IL-23 inhibitor Stelara...
Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 5 days agoExcluding sales from J&J’s COVID-19 vaccine, operational sales grew 8.3%. Higher sales of key...
Earnings call: AbbVie projects robust growth and diversified pipeline By Investing.com
Investing.com· 6 days agoWith a growth platform that accounts for 80% of AbbVie's business, the company saw mid-teens growth...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. -...
Benzinga· 16 hours agoTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech ALVO, today announced the availability of SIMLANDI (adalimumab-ryvk) injection ...
May 15, 2024, R-C Letters to the Editor
The Record-Courier· 6 days agoLetters to the Editor
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease...
The Parsons Sun· 4 days ago- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)
Americans Are Spending the Most Money on These 25 Prescription Drugs
Healthline· 5 days agoThe diabetes and weight loss medication semaglutide (Ozempic, Wegovy, and Rybelsus) topped the list....
Alvotech (ALVO) Scheduled to Post Quarterly Earnings on Tuesday
ETF DAILY NEWS· 3 days agoAlvotech (NYSE:ALVO – Get Free Report) will post its quarterly earnings results after the market closes on Tuesday, May 21st. Individual interested in participating in the company’s earnings ...